Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation

Ryohei Miyata, Motohide Shimazu, Minoru Tanabe, Shigeyuki Kawachi, Ken Hoshino, Go Wakabayashi, Yoko Kawai, Masaki Kitajima

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Thrombotic microangiopathy (TMA) may develop after living donor liver transplantation (LDLT), but the mechanism is not fully understood. We retrospectively analyzed all patients undergoing LDLT at our center, including TMA patients, to elucidate the clinical characteristics and presentation and to determine which patients have a higher risk of occurrence of TMA. In all, 57 adult patients were reviewed after LDLT at our institution. TMA was diagnosed by sudden and severe thrombocytopenia, followed by hemolytic anemia with fractionated erythrocytes in the blood smear. Clinical features were compared between the TMA group and the non-TMA group. Of the 57 patients, 4 were diagnosed with posttransplantation TMA. ABO blood group (ABO)-incompatibility, cyclophosphamide (CPA), and recipient blood group (type O) were closely correlated with the occurrence of TMA. Thrombocytopenia appeared 1 to 5 days before hemolytic anemia. Coagulative function markers stayed at the same level after TMA, while marked elevation was shown in fibrinolytic function markers such as plasminogen activator inhibitor type 1 (PAI-1). TMA occurred at a higher prevalence in ABO-incompatible graft recipients. Additional factors associated with ABO-incompatible transplantation, such as an overdose of immunosuppressants, may affect the likelihood of TMA. Sudden and severe thrombocytopenia presented before hemolytic anemia and the serum levels of PAI-1 correlated well with the clinical course of TMA. In conclusion early recognition of thrombocytopenia and elevation of PAI-1 is crucial to diagnose TMA especially in ABO-incompatible LDLT.

Original languageEnglish
Pages (from-to)1455-1462
Number of pages8
JournalLiver Transplantation
Volume13
Issue number10
DOIs
Publication statusPublished - 2007 Oct

Fingerprint

Thrombotic Microangiopathies
Living Donors
Liver Transplantation
Hemolytic Anemia
Plasminogen Activator Inhibitor 1
Thrombocytopenia
Blood Group Incompatibility
Immunosuppressive Agents
Blood Group Antigens
Cyclophosphamide

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Miyata, R., Shimazu, M., Tanabe, M., Kawachi, S., Hoshino, K., Wakabayashi, G., ... Kitajima, M. (2007). Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation. Liver Transplantation, 13(10), 1455-1462. https://doi.org/10.1002/lt.21253

Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation. / Miyata, Ryohei; Shimazu, Motohide; Tanabe, Minoru; Kawachi, Shigeyuki; Hoshino, Ken; Wakabayashi, Go; Kawai, Yoko; Kitajima, Masaki.

In: Liver Transplantation, Vol. 13, No. 10, 10.2007, p. 1455-1462.

Research output: Contribution to journalArticle

Miyata, R, Shimazu, M, Tanabe, M, Kawachi, S, Hoshino, K, Wakabayashi, G, Kawai, Y & Kitajima, M 2007, 'Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation', Liver Transplantation, vol. 13, no. 10, pp. 1455-1462. https://doi.org/10.1002/lt.21253
Miyata, Ryohei ; Shimazu, Motohide ; Tanabe, Minoru ; Kawachi, Shigeyuki ; Hoshino, Ken ; Wakabayashi, Go ; Kawai, Yoko ; Kitajima, Masaki. / Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation. In: Liver Transplantation. 2007 ; Vol. 13, No. 10. pp. 1455-1462.
@article{ee65fa6db6ca4bd1bd2a12c87cfb5ced,
title = "Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation",
abstract = "Thrombotic microangiopathy (TMA) may develop after living donor liver transplantation (LDLT), but the mechanism is not fully understood. We retrospectively analyzed all patients undergoing LDLT at our center, including TMA patients, to elucidate the clinical characteristics and presentation and to determine which patients have a higher risk of occurrence of TMA. In all, 57 adult patients were reviewed after LDLT at our institution. TMA was diagnosed by sudden and severe thrombocytopenia, followed by hemolytic anemia with fractionated erythrocytes in the blood smear. Clinical features were compared between the TMA group and the non-TMA group. Of the 57 patients, 4 were diagnosed with posttransplantation TMA. ABO blood group (ABO)-incompatibility, cyclophosphamide (CPA), and recipient blood group (type O) were closely correlated with the occurrence of TMA. Thrombocytopenia appeared 1 to 5 days before hemolytic anemia. Coagulative function markers stayed at the same level after TMA, while marked elevation was shown in fibrinolytic function markers such as plasminogen activator inhibitor type 1 (PAI-1). TMA occurred at a higher prevalence in ABO-incompatible graft recipients. Additional factors associated with ABO-incompatible transplantation, such as an overdose of immunosuppressants, may affect the likelihood of TMA. Sudden and severe thrombocytopenia presented before hemolytic anemia and the serum levels of PAI-1 correlated well with the clinical course of TMA. In conclusion early recognition of thrombocytopenia and elevation of PAI-1 is crucial to diagnose TMA especially in ABO-incompatible LDLT.",
author = "Ryohei Miyata and Motohide Shimazu and Minoru Tanabe and Shigeyuki Kawachi and Ken Hoshino and Go Wakabayashi and Yoko Kawai and Masaki Kitajima",
year = "2007",
month = "10",
doi = "10.1002/lt.21253",
language = "English",
volume = "13",
pages = "1455--1462",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation

AU - Miyata, Ryohei

AU - Shimazu, Motohide

AU - Tanabe, Minoru

AU - Kawachi, Shigeyuki

AU - Hoshino, Ken

AU - Wakabayashi, Go

AU - Kawai, Yoko

AU - Kitajima, Masaki

PY - 2007/10

Y1 - 2007/10

N2 - Thrombotic microangiopathy (TMA) may develop after living donor liver transplantation (LDLT), but the mechanism is not fully understood. We retrospectively analyzed all patients undergoing LDLT at our center, including TMA patients, to elucidate the clinical characteristics and presentation and to determine which patients have a higher risk of occurrence of TMA. In all, 57 adult patients were reviewed after LDLT at our institution. TMA was diagnosed by sudden and severe thrombocytopenia, followed by hemolytic anemia with fractionated erythrocytes in the blood smear. Clinical features were compared between the TMA group and the non-TMA group. Of the 57 patients, 4 were diagnosed with posttransplantation TMA. ABO blood group (ABO)-incompatibility, cyclophosphamide (CPA), and recipient blood group (type O) were closely correlated with the occurrence of TMA. Thrombocytopenia appeared 1 to 5 days before hemolytic anemia. Coagulative function markers stayed at the same level after TMA, while marked elevation was shown in fibrinolytic function markers such as plasminogen activator inhibitor type 1 (PAI-1). TMA occurred at a higher prevalence in ABO-incompatible graft recipients. Additional factors associated with ABO-incompatible transplantation, such as an overdose of immunosuppressants, may affect the likelihood of TMA. Sudden and severe thrombocytopenia presented before hemolytic anemia and the serum levels of PAI-1 correlated well with the clinical course of TMA. In conclusion early recognition of thrombocytopenia and elevation of PAI-1 is crucial to diagnose TMA especially in ABO-incompatible LDLT.

AB - Thrombotic microangiopathy (TMA) may develop after living donor liver transplantation (LDLT), but the mechanism is not fully understood. We retrospectively analyzed all patients undergoing LDLT at our center, including TMA patients, to elucidate the clinical characteristics and presentation and to determine which patients have a higher risk of occurrence of TMA. In all, 57 adult patients were reviewed after LDLT at our institution. TMA was diagnosed by sudden and severe thrombocytopenia, followed by hemolytic anemia with fractionated erythrocytes in the blood smear. Clinical features were compared between the TMA group and the non-TMA group. Of the 57 patients, 4 were diagnosed with posttransplantation TMA. ABO blood group (ABO)-incompatibility, cyclophosphamide (CPA), and recipient blood group (type O) were closely correlated with the occurrence of TMA. Thrombocytopenia appeared 1 to 5 days before hemolytic anemia. Coagulative function markers stayed at the same level after TMA, while marked elevation was shown in fibrinolytic function markers such as plasminogen activator inhibitor type 1 (PAI-1). TMA occurred at a higher prevalence in ABO-incompatible graft recipients. Additional factors associated with ABO-incompatible transplantation, such as an overdose of immunosuppressants, may affect the likelihood of TMA. Sudden and severe thrombocytopenia presented before hemolytic anemia and the serum levels of PAI-1 correlated well with the clinical course of TMA. In conclusion early recognition of thrombocytopenia and elevation of PAI-1 is crucial to diagnose TMA especially in ABO-incompatible LDLT.

UR - http://www.scopus.com/inward/record.url?scp=35448947412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448947412&partnerID=8YFLogxK

U2 - 10.1002/lt.21253

DO - 10.1002/lt.21253

M3 - Article

VL - 13

SP - 1455

EP - 1462

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 10

ER -